All Brands Owned by Roquette Frères

Is Roquette publicly traded?
No. Roquette Frères is a private, family-owned company with no stock exchange listing. The Roquette family holds the share capital through a holding structure and has controlled the business across five generations since 1933. Financial results are disclosed voluntarily through annual reports and press releases rather than regulatory filings.

Who owns Roquette?
Roquette is owned by members of the Roquette family, descendants of founders Dominique and Germain Roquette. The family controls the board while professional managers run daily operations. Thierry Fournier has served as chief executive, leading the group through the 2025 acquisition of IFF Pharma Solutions.

When was Roquette founded?
Roquette was founded in 1933 by brothers Dominique and Germain Roquette in Lestrem, northern France, originally as a potato starch producer serving local farmers. It expanded into wheat and corn processing after World War II and into pharmaceutical ingredients and plant proteins from the 2000s onward.

What does Roquette make?
Roquette converts plant crops into starches, sweeteners, polyols, fibers, and proteins for food manufacturers, and excipients and specialty ingredients for pharmaceutical companies. Its best-known product lines are NUTRALYS pea protein for food applications and, after the 2025 IFF acquisition, Avicel and METHOCEL excipients for drug tablets.

How big is Roquette?
In 2025 Roquette reported turnover of EUR 4,877 million and current EBITDA of EUR 612 million. It employs more than 11,000 people at over 40 manufacturing sites and 20 R&D centers, selling to customers in more than 150 countries. It is one of the largest family-owned ingredient companies in the world.

What did Roquette buy in 2025?
On May 1, 2025, Roquette completed the acquisition of IFF Pharma Solutions for a reported approximately $2.85 billion, the largest deal in its history. The business adds excipients including Avicel microcrystalline cellulose and METHOCEL, making Roquette the global leader in oral solid dosage form excipients and expanding its Health & Pharma Solutions unit to 27 percent of sales.